Refine by
Surgery Solutions For Breast Reconstruction Articles & Analysis: Older
28 news found
LATTICE MEDICAL, announces the closing of a second round of financing of 8 million euros. This round was led by the historical funds Finovam Gestion, Nord France Amorçage and WiSEED alongside the Captech Santé fund. The European Commission, via its EIC Fund, and Santelys are co-investing. The financing round is completed by non-dilutive financing, in the form of a grant and debt ...
After the entry into clinical phase announced in early July 2022, LATTICE MEDICAL, announces the success of the first breast reconstruction operation with the MATTISSE implant. The operation took place on July 12 at the Institute of Clinical Oncology, Tbilisi, Georgia. It was conducted by Pr Gia Nemsdaze and his team, and in the presence of the co-founders of Lattice Medical, Pr. Pierre ...
OnLume has received 510(k) clearance from the U.S. Food & Drug Administration (“FDA”) to market its first product, a fluorescence guided surgery (FGS) system. The OnLume Imaging System is indicated for fluorescence imaging of blood flow and tissue perfusion before, during, and after vascular, gastrointestinal, organ transplant, plastic, reconstructive, and micro surgeries. This ...
3DBio Therapeutics (3DBio), a clinical-stage regenerative medicine company, and the Microtia-Congenital Ear Deformity Institute announced they have conducted a human ear reconstruction using the AuriNovo™ implant, an investigational, patient-matched, 3D-bioprinted living tissue ear implant. The groundbreaking reconstructive procedure in the first-in-human Phase 1/2a clinical trial is ...
” The Versius® Surgical Robotic System Versius® resets expectations of robotic surgery. Versius fits into virtually any operating room set-up and integrates seamlessly into existing workflows, increasing the likelihood of robotic minimal access surgery (MAS). ...
Sonavex scored FDA clearance for its technology that uses ultrasound imaging and deep learning to deliver blood flow data on demand. The EchoSure system is cleared for use with the company’s EchoMark bioresorbable tissue markers, which got the agency’s nod in June. “The key goal is to be able to detect the problems associated with microvascular and vascular surgeries with ...
Checkpoint Surgical, Inc., the leader in intraoperative nerve repair stimulation technology, today announced it has enrolled the first patient in its multi-center clinical study of the company’s breakthrough nerve regeneration technology. The patient was enrolled at The Ohio State University, one of four sites actively enrolling patients in the double-blind, randomized clinical trial. Other ...
The installation of the NGB (Next-Generation Bioprinting) robotic bioprinting platform developed by Poietis in the Advanced Therapy Medicinal Product (ATMP) manufacturing area of the Hôpital de la Conception represents a world premiere and opens up very promising perspectives in regenerative medicine. The objective is now to start the first clinical trial of a 3D printed ...
ByPoietis
Next Science Limited (ASX:NXS) (Next Science) is pleased to announce that it has signed a multi-year distribution agreement with NASDAQ listed medical technology company, TELA Bio, Inc in relation to the supply of a white labelled version of Next Science’s proprietary XPERIENCETM No Rinse Antimicrobial Solution. The new agreement grants TELA Bio, Inc exclusive rights ...
CALCl, Italy, July 13, 2021- Medical Microinstruments (MMI) SpA, a robotics company dedicated to improving clinical outcomes for patients undergoing microsurgery, announced today that MMI's Symani® Surgical System was successfully used at Careggi University Hospital Florence by Prof. Marco Innocenti and his team in a complex, post-traumatic limb reconstruction that saved a patient's arm from ...
Alume Biosciences, Inc., a clinical stage biotechnology company developing nerve-targeted pharmaceuticals for surgical and therapeutic use, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its lead compound ALM-488. ALM-488 is an investigational fluorescently labelled nerve targeting pharmaceutical being developed as an adjunct for the ...
The University of Chicago Medicine has announced today that it is now enrolling patients into LymphBridge, a randomized clinical study to evaluate a novel investigational surgical device for the treatment of breast cancer-related lymphedema. This study is sponsored by Fibralign Corporation with funding provided by the National Cancer Institute (NCI) and being led by world-renowned microsurgeon ...
NTX-001 is a potentially transformative adjunctive treatment for peripheral nerve injuries, using a propriety system for the reconnection of severed nerves. Neuraptive plans to conduct a Phase 2 Multicenter, Randomized, Controlled Study Evaluating the Safety and Efficacy of NTX-001 versus Standard of Care in Treatment and Prevention of Facial Paralysis Requiring Surgical Repair. ...
Asensus Surgical, Inc. (formerly TransEnterix, Inc.) (NYSE American: TRXC) , a medical device company that is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery™, today announced the Company has received an additional FDA clearance for the Senhance Surgical System which allows for indication expansion in general surgery in the United ...
OrthoGrid® Systems, Inc., a global medtech leader on a mission to digitally transform intraoperative musculoskeletal surgery, announces the publication of new clinical data supporting the use of its analog and digital technology in the Journal of Arthroplasty (JOA). The article, entitled “Comparison of Component Placement Accuracy Using Two Intraoperative Fluoroscopic Grid Technologies ...
BioAesthetics Corporation today announced a clinical study of its nipple reconstruction graft will be performed at Stanford Medicine beginning in 2021. The BioAesthetics® NACgraft™ biologic matrix is a decellularized skin allograft of the human nipple-areolar complex (NAC) intended to replace the NAC when lost due to mastectomy or other procedure. BioAesthetics hopes the NACgraft will ...
Experienced healthcare industry executive with 35 years of experience Additions to the board of directors to support the company's advancing its lead program, NTX-001, along with its pipeline products Neuraptive Therapeutics, Inc. (Neuraptive), a clinical-stage biotechnology company dedicated to developing novel therapeutics and medical products for the treatment of peripheral nerve ...
Neuraptive Therapeutics, Inc. (Neuraptive), a clinical-stage biotechnology company dedicated to developing novel therapeutics and medical products for treatment of peripheral nerve injuries (PNI), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its franchise therapeutic product, NTX-001, in the treatment of patients with peripheral nerve ...
Neuraptive Therapeutics Announces FDA Clearance of IND Application for NTX-001, a Novel Approach for the Treatment of Patients with Peripheral Nerve Injuries "We are pleased to have received clearance for the company’s first IND, and are excited to initiate the trial later this year," said Evan Tzanis, Executive Vice President and Head of Research and Development. "We look forward to ...
Nerve transfer surgery has enabled 13 young adults with complete paralysis to regain movement and function in their elbows and hands, according to the largest case series of this technique in people with tetraplegia (paralysis of both the upper and lower limbs), published in The Lancet. During the surgery, Australian surgeons attached functioning nerves above the spinal injury to paralysed ...